Clinical trial NCT03236090: Effect of Vivomixx® on Neuroinflammation in Patients Withs Cirrhosis
Official title: Study of the Effect of Vivomixx® on Neuroinflammation Ans Systemic Inflammatory Response in Patients With Cirrhosis
Study type: INTERVENTIONAL
Overall status: WITHDRAWN
Phase: NA
Conditions: Cirrhosis, Liver
Keywords: Cirrhosis
Probiotics
Systemic inflammation
neuroinflammation
Cognitive function
Bacterial translocation
Lead sponsor: Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau
Sponsor class: OTHER
Collaborators: name: Spanish Clinical Research Network - SCReN
First posted: 2017-08-01
Enrollment: 0
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Intervention model description: Decompensated patients with cirrhosis:

1. Outpatients with refractory ascites (substudy 1) (n=20)
2. Patients hospitalized because bacterial infection (substudy 2) (n=30)
Primary purpose: TREATMENT

Brief summary: Study Design:

Double-blind randomized placebo-controlled clinical trial

Study Duration:

2 years

Study Center:

Single center Hospital de la Santa Creu i Sant Pau, Barcelona

Objectives:

To assess the effect of Vivomixx® on neuroinflammation and systemic inflammatory response in patients with cirrhosis

Detailed description: Study variables Main variables

* Neuroinflammation
* Systemic inflammatory response Secondary variables
* Cognitive function
* Bacterial translocation
* Intestinal barrier
* Systemic oxidative damage
* Time until SBP or other bacterial infection resolution in patients with infections
* Incidence of complications of cirrhosis and mortality during the study 40 patients, 20 and 30 in each of the two substudies, respectively Diagnosis and Main Inclusion Criteria
* Decompensated patients with cirrhosis:

  1. Outpatients with refractory ascites (substudy 1) (n=20)
  2. Patients hospitalized because bacterial infection (substudy 2) (n=30)

Study Product:

Vivomixx®sachets containing 450 x 109 bacteria, 2 every 12 hours (n=25), or placebo (n=25)

Duration of administration:

30 days Follow up The following patients' assessments will be performed: in substudy 1 at baseline and at the end of the treatment (30 days), and in substudy 2 at baseline, on day 1, day 2, day 3, day 7, at infection resolution, and at discharge or day 30.

Clinical and analytical assessments will be performed every three months after the end of the study Comparator Placebo (we evaluate the probiotic Vivomixx® vs placebo as adjunctive in addition to the standard of care) Statistical Methodology Fisher's exact test for categorical variables and Student's "t" test and Mann-Whitney and Wilcoxon tests for quantitative variables. Correlations will be assessed by Spearman test. A two-sided p value \<0.05 will be considered statistically significant

Eligibility criteria: Inclusion Criteria:

* Outpatients with cirrhosis and refractory ascites according to current definition (29) (substudy 1), and hospitalized patients with cirrhosis and an episode of bacterial infection (substudy 2) at Hospital de la Santa Creu i Sant Pau.

Cirrhosis will be diagnosed by clinical, analytical and ultrasonographic findings or by liver biopsy. SBP will be diagnosed by an ascitic fluid neutrophil count \> 250/mm3 with or without positive culture (28). Bacteremia, urinary infections, pneumonia, cellulitis, other bacterial infections and possible or suspected infections will be diagnosed according to current guidelines (13,14,28). All patients with SBP, bacteremia or pneumonia will be included. However patients with urinary infections, cellulitis or suspected infection these non-SBP infections will be required to fulfil the following requirements: at least two criteria of SIRS (systemic inflammatory response syndrome) (Annex I) (30) and CRP (C-reactive protein) \>= 10 mg/dl (28).

Exclusion Criteria:

* Advanced hepatocellular carcinoma (beyond Milan's criteria) or any other malignancy determining a poor short-term prognosis.
* Advanced liver insufficiency \[MELD (model for end-stage liver disease) \>25\].
* Marked symptomatic comorbidities (neurological, cardiac, pulmonary, renal, psychiatric, HIV infection).
* Septic shock, ileus, need for tracheal intubation or intensive care unit.
* Immunomodulatory drugs.
* In substudy 1, any infection at inclusion in the study.

Primary outcomes:
measure: Change in neuroinflammation
timeFrame: Change from baseline at 30 days
measure: Change in neuroinflammation
timeFrame: Change from baseline at 3 days
Secondary outcomes:
Other outcomes:
Locations:
city: Barcelona
country: Spain
facility: Hospital de la Santa Creu i Sant Pau
Study officials:
References: